Fibronox, L.L.C.
Alpharetta, GA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
Parent
Alpharetta, GA
PLFMB86HXNN4
-
Parent
Alpharetta, GA
PLFMB86HXNN4
- SAM.gov registration date
- Physical address
- 1805 Bethany Way, Alpharetta, GA 30004, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
About the company
Fibronox, L.L.C., doing business as Fibronox LLC, is a woman-owned small business registered to receive federal government awards since January 2, 2019. The company specializes in developing innovative therapeutic approaches for fibrotic disorders, particularly focusing on age-related fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). Fibronox's primary focus appears to be on the research and development of novel drug candidates targeting specific enzymes and pathways involved in fibrogenesis. The company collaborates with academic institutions and leverages cutting-edge scientific knowledge to advance potential treatments for devastating fibrotic conditions that currently have limited therapeutic options.
Fibronox has received multiple Project Grant awards from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). These grants support the company's efforts in developing and evaluating potential treatments for pulmonary fibrosis and other fibrotic diseases. One significant project involves the preclinical development of NOX4 inhibitors as a novel therapeutic approach for pulmonary fibrosis, with a $954,681 grant awarded to advance the top candidates through rigorous validation, selectivity evaluation, and determination of therapeutic indices. Another project, supported by a $286,739 grant, focuses on repurposing FDA-approved Nrf2 activators as inhaled therapy for IPF, assessing their clinical translatability using human ex vivo lung models and rodent studies. Additionally, Fibronox has worked on therapeutic targeting of NOX2 and NOX4 in Duchenne muscular dystrophy, demonstrating the company's broader interest in addressing various fibrotic and oxidative stress-related conditions. These research initiatives aim to develop more effective treatments for age-associated fibrotic disorders, potentially offering new hope for patients suffering from these debilitating conditions.
Quick answers
Is Fibronox, L.L.C. registered in SAM.gov?
Yes. Fibronox, L.L.C.'s SAM.gov registration is active through May 29, 2027.
What is Fibronox, L.L.C.'s CAGE code?
Fibronox, L.L.C.'s CAGE code is 885T8, and its Unique Entity ID (UEI) is RJEND8BC5974.
What is Fibronox, L.L.C.'s most recent federal award?
Fibronox, L.L.C.'s most recent federal grant award is Advanced pre-clinical development of NOX4 inhibitors for pulmonary fibrosis (R44HL172475), from National Heart Lung and Blood Institute (NIH), on June 1, 2024.
On GovTribe
See Fibronox, L.L.C.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors